Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs



Rating:

Share or cite this content

Citations should be made in the following way:
J. Naccache (Paris, France), S. Jouneau (Rennes, France), M. Didier (Bobigny, France), R. Borie (Paris, France), M. Cachanado (Paris, France), A. Bourdin (Montpellier, France), M. Reynaud-Gaubert (Marseille, France), P. Bonniaud (Dijon, France), D. Israel-Biet (Paris, France), G. Prevot (Toulouse, France), S. Hirschi (Strasbourg, France), F. Lebargy (Reims, France), S. Marchand-Adam (Tours, France), N. Bautin (Lille, France), J. Traclet (Lyon, France), E. Gomez (Nancy, France), S. Leroy (Nice, France), F. Gagnadoux (Angers, France), F. Rivière (Clamart, France), E. Bergot (Caen, France), A. Gondouin (Besançon, France), E. Blanchard (Bordeaux, France), A. Parrot (Paris, France), F. Blanc (Nantes, France), A. Chabrol (Suresnes, France), S. Dominique (Rouen, France), A. Gibelin (Paris, France), A. Tazi (Paris, France), L. Berard (Paris, France), P. Brillet (Bobigny, France), M. Debray (Paris, France), A. Rousseau (Paris, France), M. Kerjouan (Rennes, France), O. Freynet (Bobgny, France), M. Dombret (Paris, France), A. Gamez (Montpellier, France), A. Nieves (Marseille, France), G. Beltramo (Dijon, France), J. Pastré (Paris, France), A. Le Borgne-Krams (Toulouse, France), T. Dégot (Strasbourg, France), C. Launois (Reims, France), L. Plantier (Tours, France), L. Wémeau-Stervinou (Lille, France), J. Cadranel (Paris, France), C. Chenivesse (Lille, France), D. Valeyre (Bobigny, France), B. Crestani (Paris, France), V. Cottin (Lyon, France), T. Simon (Paris, France), H. Nunes (Bobigny, France), On Behalf Of The Orphalung Network. RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial. 2903

Member's Comments

No comment yet.

Related content which might interest you: Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial Source: Annual Congress 2010 - COPD exacerbation Year: 2010 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022 A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013 The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study Source: Eur Respir J 2001; 18: Suppl. 33, 419s Year: 2001 High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002 A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006